#BEGIN_DRUGCARD DB03556

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C18H38O9

# Chemical_IUPAC_Name:
3,6,9,12,15,18,21,24-octaoxahexacosan-1-ol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400

# HET_ID:
PE5

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C18H38O9/c1-2-20-5-6-22-9-10-24-13-14-26-17-18-27-16-15-25-12-11-23-8-7-21-4-3-19/h19H,2-18H2,1H3

# InChI_Key:
InChIKey=CUDPPTPIUWYGFI-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3556

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
398.4889

# Molecular_Weight_Mono:
398.251582814

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1WMA

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.38

# Predicted_LogS:
-3.2

# Predicted_Water_Solubility:
2.32e-01 g/l

# Primary_Accession_No:
DB03556

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
657096

# PubChem_Substance_ID:
46506675

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02539

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCOCCOCCOCCOCCOCCOCCOCCOCCO

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:22 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CBR1

# Phase_1_Metabolizing_Enzyme_1_ID:
5251

# Phase_1_Metabolizing_Enzyme_1_Name:
Carbonyl reductase [NADPH] 1

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Carbonyl reductase [NADPH] 1
MSSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFH
QLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRD
VCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTK
KGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKA
TKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P16152

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CBR1

# Drug_Target_1_GenBank_ID_Gene:
J04056

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
CBR1

# Drug_Target_1_Gene_Sequence:
>834 bp
ATGTCGTCCGGCATCCATGTAGCGCTGGTGACTGGAGGCAACAAGGGCATCGGCTTGGCC
ATCGTGCGCGACCTGTGCCGGCTGTTCTCGGGGGACGTGGTGCTCACGGCGCGGGACGTG
ACGCGGGGCCAGGCGGCCGTACAGCAGCTGCAGGCGGAGGGCCTGAGCCCGCGCTTCCAC
CAGCTGGACATCGACGATCTGCAGAGCATCCGCGCCCTGCGCGACTTCCTGCGCAAGGAG
TACGGGGGCCTGGACGTGCTGGTCAACAACGCGGGCATCGCCTTCAAGGTTGCTGATCCC
ACACCCTTTCATATTCAAGCTGAAGTGACGATGAAAACAAATTTCTTTGGTACCCGAGAT
GTGTGCACAGAATTACTCCCTCTAATAAAACCCCAAGGGAGAGTGGTGAACGTATCTAGC
ATCATGAGCGTCAGAGCCCTTAAAAGCTGCAGCCCAGAGCTGCAGCAGAAGTTCCGCAGT
GAGACCATCACTGAGGAGGAGCTGGTGGGGCTCATGAACAAGTTTGTGGAGGATACAAAG
AAGGGAGTGCACCAGAAGGAGGGCTGGCCCAGCAGCGCATACGGGGTGACGAAGATTGGC
GTCACCGTTCTGTCCAGGATCCACGCCAGGAAACTGAGTGAGCAGAGGAAAGGGGACAAG
ATCCTCCTGAATGCCTGCTGCCCAGGGTGGGTGAGAACTGACATGGCGGGACCCAAGGCC
ACCAAGAGCCCAGAAGAAGGTGCAGAGACCCCTGTGTACTTGGCCCTTTTGCCCCCAGAT
GCTGAGGGTCCCCATGGACAATTTGTTTCAGAGAAGAGAGTTGAACAGTGGTGA

# Drug_Target_1_General_Function:
Involved in oxidoreductase activity

# Drug_Target_1_General_References:
10830953	Hattori M, Fujiyama A, Taylor TD, Watanabe H, Yada T, Park HS, Toyoda A, Ishii K, Totoki Y, Choi DK, Groner Y, Soeda E, Ohki M, Takagi T, Sakaki Y, Taudien S, Blechschmidt K, Polley A, Menzel U, Delabar J, Kumpf K, Lehmann R, Patterson D, Reichwald K, Rump A, Schillhabel M, Schudy A, Zimmermann W, Rosenthal A, Kudoh J, Schibuya K, Kawasaki K, Asakawa S, Shintani A, Sasaki T, Nagamine K, Mitsuyama S, Antonarakis SE, Minoshima S, Shimizu N, Nordsiek G, Hornischer K, Brant P, Scharfe M, Schon O, Desario A, Reichelt J, Kauer G, Blocker H, Ramser J, Beck A, Klages S, Hennig S, Riesselmann L, Dagand E, Haaf T, Wehrmeyer S, Borzym K, Gardiner K, Nizetic D, Francis F, Lehrach H, Reinhardt R, Yaspo ML: The DNA sequence of human chromosome 21. Nature. 2000 May 18;405(6784):311-9.
1921984	Forrest GL, Akman S, Doroshow J, Rivera H, Kaplan WD: Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity. Mol Pharmacol. 1991 Oct;40(4):502-7.
2182121	Forrest GL, Akman S, Krutzik S, Paxton RJ, Sparkes RS, Doroshow J, Felsted RL, Glover CJ, Mohandas T, Bachur NR: Induction of a human carbonyl reductase gene located on chromosome 21. Biochim Biophys Acta. 1990 Apr 6;1048(2-3):149-55.
3141401	Wermuth B, Bohren KM, Heinemann G, von Wartburg JP, Gabbay KH: Human carbonyl reductase. Nucleotide sequence analysis of a cDNA and amino acid sequence of the encoded protein. J Biol Chem. 1988 Nov 5;263(31):16185-8.
9740676	Watanabe K, Sugawara C, Ono A, Fukuzumi Y, Itakura S, Yamazaki M, Tashiro H, Osoegawa K, Soeda E, Nomura T: Mapping of a novel human carbonyl reductase, CBR3, and ribosomal pseudogenes to human chromosome 21q22.2. Genomics. 1998 Aug 15;52(1):95-100.

# Drug_Target_1_HGNC_ID:
HGNC:1548

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5251

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
30375

# Drug_Target_1_Name:
Carbonyl reductase [NADPH] 1

# Drug_Target_1_Number_of_Residues:
277

# Drug_Target_1_PDB_ID:
1WMA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00106	adh_short

# Drug_Target_1_Protein_Sequence:
>Carbonyl reductase [NADPH] 1
MSSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFH
QLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRD
VCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTK
KGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKA
TKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the reduction of a wide variety of carbonyl compounds including the antitumor anthracycline antibiotics. Can convert prostaglandin E2 to prostaglandin F2-alpha

# Drug_Target_1_SwissProt_ID:
P16152

# Drug_Target_1_SwissProt_Name:
CBR1_HUMAN

# Drug_Target_1_Synonyms:
15-hydroxyprostaglandin dehydrogenase [NADP+]
EC 1.1.1.184
EC 1.1.1.189
EC 1.1.1.197
NADPH-dependent carbonyl reductase 1
Prostaglandin 9-ketoreductase
Prostaglandin-E(2) 9-reductase

# Drug_Target_1_Theoretical_pI:
8.49

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasmic

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
Not Available

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AE004417

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
VC_A0897

# Drug_Target_2_Gene_Sequence:
>717 bp
ATGATCAACCATAAAATTTTCCCAACTGCGGATGCCGTAGTGAAAAGCCTTGCCGACGAT
ATGTTGGCGTACAGCCAGCAAGGTCAGCCAGTACACATTTCCTTATCTGGCGGCAGCACA
CCAAAAATGCTGTTTAAGCTTTTGGCAAGCCAGCCTTACGCCAACGACATTCAGTGGAAA
AACCTGCATTTCTGGTGGGGGGATGAACGCTGTGTGGCACCGGATGACGCAGAAAGCAAC
TACGGTGAAGCCAATGCGCTGCTGTTTAGCAAAATCAACATGCCTGCACAGAACATTCAC
CGCATTCTGGGTGAAAACGAGCCACAAGCTGAAGCAGAACGTTTTGCTCAAGCGATGGCG
CATGTGATCCCAACCGAAAACGGCACGCCTGTGTTTGATTGGATCCTACTGGGTGTCGGT
GCGGATGGTCATACCGCATCCCTGTTCCCAGGGCAAACCGACTATGCAGACGCCAATCTT
TCGGTGGTGGCAAGCCATCCAGAATCTGGGCAACTACGCGTTTCAAAAACCGCGAAAGTG
CTGCAAGCCGCAAAACGCATCAGTTATCTCGTTCTTGGCGCAGGTAAAGCCGAGATCGTA
GAACAAATTCACACCACTCCAGCCGAACAACTGCCTTATCCGGCAGCCAAAATTCACTCC
ACTTCAGGAGTGACGGAGTGGTACTTAGATTCAGACGCCGCAGCAAAGATTGCGTGA

# Drug_Target_2_General_Function:
Involved in 6-phosphogluconolactonase activity

# Drug_Target_2_General_References:
10952301	Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Umayam L, Gill SR, Nelson KE, Read TD, Tettelin H, Richardson D, Ermolaeva MD, Vamathevan J, Bass S, Qin H, Dragoi I, Sellers P, McDonald L, Utterback T, Fleishmann RD, Nierman WC, White O, Salzberg SL, Smith HO, Colwell RR, Mekalanos JJ, Venter JC, Fraser CM: DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature. 2000 Aug 3;406(6795):477-83.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
5354

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
25804

# Drug_Target_2_Name:
DevB protein

# Drug_Target_2_Number_of_Residues:
238

# Drug_Target_2_PDB_ID:
1Y89

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01182	Glucosamine_iso

# Drug_Target_2_Protein_Sequence:
>DevB protein
MINHKIFPTADAVVKSLADDMLAYSQQGQPVHISLSGGSTPKMLFKLLASQPYANDIQWK
NLHFWWGDERCVAPDDAESNYGEANALLFSKINMPAQNIHRILGENEPQAEAERFAQAMA
HVIPTENGTPVFDWILLGVGADGHTASLFPGQTDYADANLSVVASHPESGQLRVSKTAKV
LQAAKRISYLVLGAGKAEIVEQIHTTPAEQLPYPAAKIHSTSGVTEWYLDSDAAAKIA

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q9KL51

# Drug_Target_2_SwissProt_Name:
Q9KL51_VIBCH

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
5.50

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB03556
